Polypeptide Attached To Or Complexed With The Agent (e.g., Protein, Antibody, Etc.) Patents (Class 424/9.34)
The region of the imaging agent responsible for binding to an in vivo target or the region of the target responsible for binding to the agent is specifically recited functionally or as a sequence of amino acids, carbohydrate residues, or nucleic acids (Class 424/9.341)
  • Targeting and imaging tumor vasculature using conjugates that bind to aminophospholipids
    Patent number: 7790860
    Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidyserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: September 7, 2010
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Sophia Ran, Rolf A. Brekken
  • Methods and kits for diagnosis of cancer and prediction of therapeutic value
    Publication number: 20100209343
    Abstract: A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.
    Type: Application
    Filed: February 17, 2010
    Publication date: August 19, 2010
    Applicant: Cornell Research Foundation, Inc.
    Inventors: Neil Bander, Joseph Osborne, Stanley J. Goldsmith, Shankar Vallabhajosula
  • CUPREDOXIN DERIVED TRANSPORT AGENTS AND METHODS OF USE THEREOF
    Publication number: 20100209355
    Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer.
    Type: Application
    Filed: April 5, 2010
    Publication date: August 19, 2010
    Inventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Arsenio Fialho
  • METAL CHELATORS AND METHODS OF THEIR USE
    Publication number: 20100189645
    Abstract: Metal chelators of Formula I and Formula II are disclosed: or a pharmaceutically acceptable salt thereof. Also disclosed are metal chelator-targeting moiety complexes, metal chelator-targeting moiety-metal conjugates, kits, and methods of their preparation and use in diagnosis and/or treatment of diseases and conditions, including, inter alia, cancer and thrombosis.
    Type: Application
    Filed: April 1, 2010
    Publication date: July 29, 2010
    Applicant: The Government of the United States of America, as represented by the Secretary, Dept. of Homeland a
    Inventors: Martin Wade Brechbiel, Thomas Clifford
  • MULTIMODAL IMAGING PROBES FOR IN VIVO TARGETED AND NON-TARGETED IMAGING AND THERAPEUTICS
    Publication number: 20100183504
    Abstract: In certain embodiments this invention provides a nanoparticle-based technology platform for multimodal in vivo imaging and therapy. The nanoparticle-based probes detects diseased cells by MRI, PET or deep tissue Near Infrared (NIR) imaging, and are capable of detecting diseased cells with greater sensitivity than is possible with existing technologies. The probes also target molecules that localize to normal or diseased cells, and initiates apoptosis of diseased cells.
    Type: Application
    Filed: June 13, 2008
    Publication date: July 22, 2010
    Inventor: Fanqing Frank Chen
  • NANOPARTICULATE PROBE FOR IN VIVO MONITORING OF TISSUE OXYGENATION
    Publication number: 20100172843
    Abstract: A new class of micro- and nano-particulate paramagnetic spin probes especially useful for magnetic resonance imaging techniques, including electron paramagnetic resonance (EPR) and magnetic resonance imaging (MRI). The probes are lithium phthalocyanine derivative compounds. Also provided are suspensions and emulsions comprising lithium phthalocyanine derivative probes. Also provided are noninvasive methods for measuring noninvasive methods of measuring oxygen concentration, oxygen partial pressure, oxygen metabolism, and nitric oxide concentration in a specific tissue, organ, or cell in vivo or in vitro.
    Type: Application
    Filed: January 15, 2010
    Publication date: July 8, 2010
    Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Periannan Kuppusamy, Ramasamy P. Pandian, Narasimham L. Parinandi, Jay L. Zweier
  • Single-Drug Multi-Ligand Conjugates for Targeted Drug Delivery
    Publication number: 20100166654
    Abstract: An adhesive is provided containing at least one synthetic polymer with receptor sites that enable the selective capture or release of a target molecule. A polymer is synthesized by polymerizing and cross-linking a functional monomer or functional copolymers in the presence of a target or template molecule allowing for reversible interactions between the polymer and the target molecule. The target molecule may be extracted from the polymer creating receptor sites complimentary to the target molecule. Alternatively, the target molecule may remain in the polymer network and be controllably released. The molecularly imprinted polymer is formulated into an adhesive. The adhesive can be used as a component in an in-vitro diagnostic device to release template molecules or to capture target molecules in vacated receptor sites in the synthetic polymer.
    Type: Application
    Filed: December 2, 2005
    Publication date: July 1, 2010
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventor: Ahmad Safavy
  • Degradable macromolecular magnetic resonance imaging contrast agents and methods thereof
    Patent number: 7745590
    Abstract: Degradable macromolecular magnetic resonance imaging contrast agents for use in various diagnostic procedures, and methods for synthesizing, using and degrading these agents, are described. The macromolecule contrast agents disclosed in various aspects of this invention are degradable gadolinium compounds which show prolonged plasma retention, and enhanced permeability and retention in solid tumors, but are still capable of being rapidly cleared from the body.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: June 29, 2010
    Assignee: University of Utah Research Foundation
    Inventors: Zheng-Rong Lu, Jindrich Kopecek, Dennis L. Parker
  • Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies
    Publication number: 20100158803
    Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.
    Type: Application
    Filed: January 7, 2010
    Publication date: June 24, 2010
    Applicant: IMMUNOMEDICS, INC.
    Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
  • Chelating agents with lipophilic carriers
    Patent number: 7727512
    Abstract: Compounds useful for associating with nanoparticle or microparticle emulsions to obtain magnetic resonance images permit control of the relaxivity of the signal and readily associate with the particulate components.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: June 1, 2010
    Assignees: Barnes-Jewish Hospital, The Dow Chemical Company
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Phillip S. Athey, Gyongyi Gulyas, Garry E. Kiefer
  • Prevention and treatment of atherosclerosis by reducing carbamylation of LDL or the effects of carbamylated LDL
    Patent number: 7722858
    Abstract: The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of measuring the level of cLDL and/or autoantibody to cLDL in a sample obtained from this individual. The invention further discloses a method of reducing carbamylation in an individual with a monomeric amino acid or other enzymatic or non-enzymatic inhibitors of carbamylation. The instant invention also provides a method to decrease the level of cLDL by direct elimination of cLDL from the blood or plasma of an individual. The invention also provides a method of treating or preventing atherosclerosis in an individual by inhibiting aggregation and/or deposition of cLDL in the individual.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: May 25, 2010
    Assignees: Board of Trustees of the University of Arkansas, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Sudhir V. Shah, Alexei G. Basnakian, Yousri M. Barri
  • MULTIMODALITY MOLECULAR IMAGING WITH THERAPEUTIC CONJUGATES
    Publication number: 20100068151
    Abstract: Disclosed are pharmaceutical compounds comprising a cell-specific targeting moiety, an anti-cell proliferation moiety, and a chelator moiety. Also disclosed are methods for treating a subject with a hyperproliferative disease, methods for diagnosing presence of a hyperproliferative disease in a subject, and methods for detecting a therapeutic response in a subject that employ the pharmaceutical compounds of the present invention.
    Type: Application
    Filed: March 11, 2009
    Publication date: March 18, 2010
    Inventors: Michael G. Rosenblum, Xiaoyuan Chen
  • Chimeric, human and humanized anti-CSAP monoclonal antibodies
    Patent number: 7670804
    Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: March 2, 2010
    Assignee: Immunomedics, Inc.
    Inventors: Hans J. Hansen, David M. Goldenberg
  • NOVEL NANOPARTICLES FOR BIOFILM TARGETING
    Publication number: 20100021391
    Abstract: The present invention is directed to novel compositions and methods utilizing nanoparticles comprising protein cages for delivery of imaging and antimicrobial agents to biofilm forming bacterial colonies.
    Type: Application
    Filed: July 13, 2007
    Publication date: January 28, 2010
    Applicant: MONTANA STATE UNIVERSITY
    Inventors: Trevor Douglas, Mark J. Young, Peter Suci
  • CANCER BIOMARKERS AND METHODS OF USE THEREOF
    Publication number: 20100003189
    Abstract: Detection methods, assay kits and reagents are provided for detecting pre-cancerous mammary epithelial cell signatures. The disclosed cell signatures comprise a collection of measurements of at least two characteristics of the mammary epithelial cells. Related imaging and diagnostic methods are also disclosed.
    Type: Application
    Filed: July 3, 2007
    Publication date: January 7, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thea D. Tlsty, Hal K. Berman, Mona L. Gauthier, Bob Y. Liu, Colleen A. Fordyce, Curtis R. Pickering, Paul A. Reynolds, Nancy Dumont, Geoffrey M. Benton
  • Chimeric, human and humanized anti-CSAp monoclonal antibodies
    Patent number: 7641891
    Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: January 5, 2010
    Assignee: Immunomedics, Inc.
    Inventors: Hans J. Hansen, David M. Goldenberg
  • Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits
    Publication number: 20090297439
    Abstract: An immuno-imaging agent for the detection of tumor cells by means of an immuno-imaging technique, including at least one of: an anti-Met monoclonal antibody, a fragment of an anti-Met monoclonal antibody containing the epitope binding region thereof, a genetically engineered antibody containing the epitope binding region of an anti-Met monoclonal antibody, a humanized antibody containing the epitope binding region of an anti-Met monoclonal antibody, or combinations thereof, wherein the anti-Met monoclonal antibody is produced by the hybridoma cell line ICLC PD 05006, and corresponding compositions and kits.
    Type: Application
    Filed: June 2, 2008
    Publication date: December 3, 2009
    Applicant: METHERESIS TRANSLATIONAL RESEARCH SA,
    Inventors: Paolo Maria Comoglio, Paolo Carminati, Guus Van Dongen
  • Antibodies against toxins and uses thereof
    Patent number: 7625559
    Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
    Type: Grant
    Filed: February 4, 2005
    Date of Patent: December 1, 2009
    Assignees: University of Massachusetts, Medarex, Inc.
    Inventors: Donna Ambrosino, Gregory J. Babcock, Teresa Broering, Robert Graziano, Hector Javier Hernandez, Israel Lowy, Robert Mandell, Deborah Molrine, William D. Thomas, Jr., Hui-Fen Zhang
  • IN VIVO IMAGING AGENTS FOR MET RECEPTOR TYROSINE KINASE
    Publication number: 20090274623
    Abstract: Provided are in vivo imaging agents comprising muteins of hTLc having detectable binding affinity for c-Met or a domain thereof, coupled to a signal generator, and the mutein coupled to a signal generator is disposed in a pharmaceutically acceptable carrier. Also provided are diagnostic methods using in vivo imaging agents comprising muteins of hTLc having detectable binding affinity for c-Met or a domain thereof.
    Type: Application
    Filed: January 30, 2008
    Publication date: November 5, 2009
    Applicant: GENERAL ELECTRIC COMPANY
    Inventors: Clifford L. Smith, Faisal Ahmed Syud, Brian Duh-Lan Lee, Matthew Sam Morrison, Michael Ernest Marino, Jason William Castle, Paul Schaffer, Gabriele Matschiner, Andreas Hohlbaum, Martin Huelsmeyer, Stefan Trentmann
  • CONTRAST AGENTS
    Publication number: 20090269284
    Abstract: The present invention relates generally to multimodal magnetic resonance imaging (MRI) contrast agents. In particular, the present invention provides a MRI contrast agent configured to manipulate both the longitudinal (T1) and transverse (T2) relaxation times of surrounding water proton spins.
    Type: Application
    Filed: September 15, 2008
    Publication date: October 29, 2009
    Applicant: Northwestern University
    Inventors: Elise A. Schultz Sikma, Mohammad Aslam, Vinayak P. Dravid, Thomas J. Meade, Bradley D. Ulrich
  • Stable isotope-labeled aromatic amino acids, method for incorporating the same in target protein and method for NMR-structural analysis of proteins
    Patent number: 7608248
    Abstract: The present invention herein provides, for instance, a stable isotope-labeled phenylalanine wherein a carbon atom of the phenyl group linked to an amino acid residue is 13C, 2 to 4 carbon atoms of the remaining 5 carbon atoms constituting the phenyl group are 12C atoms to which deuterium atoms are bonded, and the remaining carbon atoms are 13C atoms to which hydrogen atoms are linked, and a stable isotope-labeled tyrosine wherein a carbon atom of the phenyl group linked to an amino acid residue is 13C, the carbon atom bonded to the hydroxyl group (OH group) of the phenyl group is 12C or 13C, 2 to 4 carbon atoms of the remaining 4 carbon atoms constituting the phenyl group are 12C atoms to which deuterium atoms are bonded, and the remaining carbon atoms are 13C atoms to which hydrogen atoms are linked.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: October 27, 2009
    Assignee: Japan Science and Technology Agency
    Inventors: Masatsune Kainosho, Tsutomu Terauchi
  • Magnetic resonance contrast medium containing an iron-binding protein
    Publication number: 20090252688
    Abstract: An inventive principle of at least one embodiment is based on linking an iron-binding functionality in the form of a bacterial iron-binding protein to a binding element which specifically recognizes a biological structure, in order to increase a local detectable increase in the concentration of the contrast medium. In at least one embodiment of the invention, a magnetic resonance contrast medium is provided which is capable of binding by way of a binding element to a biological structure in the body of a mammal, the binding element including an isolated polypeptide. The polypeptide includes a first amino acid sequence of a bacterial iron-binding protein or a derivative thereof, wherein the bacterial iron-binding protein or said derivative thereof has an iron-binding activity. In at least one embodiment, the binding element can bind a protein.
    Type: Application
    Filed: January 22, 2008
    Publication date: October 8, 2009
    Inventor: Arne Hengerer
  • TARGETING AGENTS FOR MOLECULAR IMAGING
    Publication number: 20090246127
    Abstract: This invention discloses a method of synthesizing targeting contrast agents for molecular imaging and targeting diagnosis and therapy, targeting contrast agents and targeting therapeutic agents and the use thereof.
    Type: Application
    Filed: December 12, 2005
    Publication date: October 1, 2009
    Applicant: KONINKLIJKE PHILIPS ELECTRONICS, N.V.
    Inventors: Helga Hummel, Volker Ulrich Weiler
  • Diagnostic and Therapeutic Potential of Immune Globulin Intravenous (IGIV) Products
    Publication number: 20090232733
    Abstract: The present invention provides IGIV and IGIV enriched for binding to amyloid fibrils and to partially denatured amyloidogenic precursor polypeptides. The present invention also provides methods for obtaining IGIV enriched for binding to amyloid fibrils and to partially denatured amyloidogenic precursor polypeptides. The IGIV recognizes amyloid fibrils and partially denatured amyloidogenic precursor polypeptides. They are useful for treating diseases and conditions associated with amyloid deposition. The IGIV of the present invention also are useful for diagnosing and detecting amyloid deposition.
    Type: Application
    Filed: April 13, 2006
    Publication date: September 17, 2009
    Inventors: Brian O'Nuallain, Rudi Hrncic, Jonathan S. Wall, Alan Solomon
  • STQ Peptides
    Publication number: 20090226369
    Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured laminin with substantially greater affinity than to the native form of laminin. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo.
    Type: Application
    Filed: May 12, 2008
    Publication date: September 10, 2009
    Applicant: NEW YORK UNIVERSITY
    Inventors: Peter C. Brooks, Abebe Akalu
  • Imaging agents and methods of using same for detecting multidrug resistance in cancer
    Publication number: 20090220432
    Abstract: Compounds and methods of using such compounds in the imaging and detection of multidrug resistance cancer in a subject are provided. In particular, novel imaging agents are provided which are suitable for the detection and imaging of a multidrug resistance phenotype in cancer cells and/or tissues using non-invasive medical imaging modalities.
    Type: Application
    Filed: August 31, 2006
    Publication date: September 3, 2009
    Applicant: The Johns Hopkins University
    Inventors: Dimitri Artemov, Yoshinori Kato
  • METHODS AND COMPOSITIONS FOR THE PREPARATION AND USE OF TOXIN CONJUGATES
    Publication number: 20090214438
    Abstract: The present invention relates to methods for the preparation of toxin conjugates that are useful in vaccination and other therapies and diagnostics. In particular, methods are provided that involve a [3+2] cycloaddition between a first reactive unsaturated group on a toxin moiety and a second reactive unsaturated group on a bioactive moiety. Also provided are conjugates that are formed through this conjugation method, pharmaceutical compositions comprising these conjugates, and methods of using these pharmaceutical compositions for the treatment or diagnostic of antigen-related conditions, including tumors and infections.
    Type: Application
    Filed: December 18, 2008
    Publication date: August 27, 2009
    Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS
    Inventors: Ludger JOHANNES, Baldissera GIOVANI, Michel AZOULAY, Jean-Claude FLORENT
  • Human glycoprotein hormone superagonists and uses thereof
    Publication number: 20090214424
    Abstract: The present invention provides improved methods of imaging, targeted therapy and detection and diagnostics using modified glycoprotein hormones having increased activity over wild-type hormones.
    Type: Application
    Filed: March 18, 2005
    Publication date: August 27, 2009
    Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub
  • ENCAPSULATED NANOPARTICLES FOR COMPUTED TOMOGRAPHY IMAGING
    Publication number: 20090208409
    Abstract: A detection agent, including a polymerized liposome, a lectin, and an imaging agent, can be administered to an animal for the detection of polyps in the lower gastrointestinal tract.
    Type: Application
    Filed: February 13, 2009
    Publication date: August 20, 2009
    Applicant: The Government of the United States of America, as represented by the Secretary, DHHS
    Inventors: Ronald M. Summers, Jianwu Xie, Celeste A. Roney
  • Peptides for detection of antibody to porcine reproductive respiratory syndrome virus
    Patent number: 7572445
    Abstract: The invention provides compositions and methods for the detection and quantification of PRRSV antibodies and antibody fragments using polypeptides.
    Type: Grant
    Filed: February 24, 2006
    Date of Patent: August 11, 2009
    Assignee: IDEXX Laboratories, Inc.
    Inventor: Eugene Regis Krah, III
  • Targeting and Imaging Tumor Vasculature Using Conjugates That Bind to Aminophospholipids
    Publication number: 20090191121
    Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidyserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.
    Type: Application
    Filed: February 13, 2009
    Publication date: July 30, 2009
    Inventors: Philip E. Thorpe, Sophia Ran, Rolf A. Brekken
  • Invention concerning GLP-1 and exendin
    Publication number: 20090180953
    Abstract: In the current invention peptides, which are derived from GLP-1 (glucagon-like peptide-1) and exendin-3 and/or exendin-4, are provided which bond to the GLP-receptor and can be used, labeled or unlabeled, for the production of an agent for diagnostic and therapy of benign and malignant diseases, in which GLP-1 receptor expression plays a role.
    Type: Application
    Filed: March 2, 2007
    Publication date: July 16, 2009
    Inventors: Martin Gotthardt, Martin Behe, Thomas Behr, Burkhard J. Goke
  • Ligands binding the complex of urokinase-type plasminogen activator (uppa) and its receptor (upar) that inhibit downstream upar interactions: identification and use in diagnosis or therapy
    Publication number: 20090180952
    Abstract: Antibodies or other ligands specific for the binary uPA-uPAR complexes, for ternary complexes comprising uPA-uPAR and for complexes of uPAR and proteins other than uPA such as integrins inhibit the interaction of uPA and uPAR with additional molecules with which the complexed interact. Such antibodies or other ligands are used in diagnostic and therapeutic methods, particularly against cancer.
    Type: Application
    Filed: May 25, 2005
    Publication date: July 16, 2009
    Applicant: MELEXIS NV
    Inventors: Graham C. Parry, Andrew P. Mazar
  • MAGNETIC RESONANCE CONTRAST MEDIUM USING POLYETHYLENE GLYCOL AND MAGNETIC RESONANCE IMAGE PICK-UP METHOD
    Publication number: 20090162291
    Abstract: An object of the invention is to provide a technique that is safe and quantitative, and is capable of continuously acquiring a magnetic resonance image with a short repetition time. A magnetic resonance contrast agent comprising a polyethylene glycol containing 13C in a proportion higher than the natural abundance, or a compound labeled with the polyethylene glycol, is used to continuously acquire magnetic resonance signals by applying excitation pulses with a repetition time of 60 seconds or less.
    Type: Application
    Filed: May 14, 2007
    Publication date: June 25, 2009
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Yoshikazu Suzuki, Iwao Miura, Mitsuru Iida
  • METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF
    Publication number: 20090162290
    Abstract: The present invention provides a method for synthesis and binding methods of pentapendant enantiomer-pure chelators of formula (VII) wherein R1, R2, R3, R4 are groups forming an adequate enantiomer of the chelator; and X1-X5, Y1-Y5, Z1-Z5 each individually forming pendant chelating groups.
    Type: Application
    Filed: September 11, 2006
    Publication date: June 25, 2009
    Inventors: Ivan Benes, Simon Cihelnik, Ladislav Droz, Martin Sramek
  • ANNEXIN DERIVATIVES SUITABLE FOR PRETARGETING IN THERAPY AND DIAGNOSIS
    Publication number: 20090155170
    Abstract: The present invention provides methods and compositions for the treatment and diagnosis of diseases such as neoplastic diseases, neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and inflammatory diseases. The methods are based on the concept of pretargeting and include the administration of complexes comprising a recognizable compound A coupled to annexins, and the administration of complexes comprising of pharmaceutical or diagnostic compounds coupled to a compound B recognizing and binding to compound A to subjects. The compositions include annexins, annexin variants, that are not internalized by the target cells, derivatives thereof, and complexes thereof.
    Type: Application
    Filed: December 12, 2006
    Publication date: June 18, 2009
    Inventors: Christiaan Peter Maria Reutelingsperger, Peter Moonen, Ad Vermaire
  • Cyanovirin variant-polymer conjugates
    Patent number: 7547509
    Abstract: The present invention provides variants of cyanovirin-N and water-soluble polymer conjugates thereof, and methods of preparing such conjugates. The cyanovirin-N of the invention are particularly suited for site-selective covalent attachment of one or more water soluble polymers, to provide polymer conjugates of cyanovirin-N variants exhibiting antiviral activity.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: June 16, 2009
    Assignees: Nektar Therapeutics AL, Corporation, National Institute of Heatlh
    Inventors: M. Elizabeth Snell, Michael J. Roberts, Toshiyuki Mori, Barry R. O'Keefe, Michael R. Boyd
  • Method of screening groups of radioactive molecules and applications thereof
    Patent number: 7541157
    Abstract: The invention relates to an amplification-free method of screening groups of radioactive molecules, comprising at least the following steps: (1) the group of molecules is administered to at least one animal; (2) at least one of the animals is slaughtered and the tissue distribution of the radioactivity of the molecules administered is analyzed in vivo; (3) sections of tissue or organs in which a radioactivity signal is detected are selected; (4) radioactive fractions from the sections of tissue or organs are isolated using suitable techniques such as chromatography and/or extraction techniques; and (5) the molecule(s) from the radioactive fractions obtained in step 4 are characterized using suitable analysis techniques such as chromatography and/or mass spectrometry.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: June 2, 2009
    Assignee: Commissariat a l'Energie Atomique
    Inventors: Vincent Dive, André Menez, Reto Stocklin, Bertrand Tavitian, Fabrice Beau, Bertrand Czarny, Joël Cotton
  • SUPRAMOLECULAR AGGREGATES CONTAINING CHELATING AGENTS AND BIOACTIVE PEPTIDES AS EFFECTIVE AND SELECTIVE DELIVERY TOOLS FOR DRUGS AND CONTRAST AGENTS IN MRI OR NUCLEAR MEDICINE
    Publication number: 20090130018
    Abstract: The invention relates to supramolecular aggregates obtained by coaggregation of two monomers: —a first monomer containing a paramagnetic or radioactive metal ion complexed by a chelating agent having a lipophilic moiety, —a second monomer containing a bioactive peptide linked to a lipophilic moiety through an organic spacer. The aggregates are selectively driven by the exposed bioactive peptide on a desired biological target. The aggregates (micelles, vesicles or liposomes) could entrap on their inner region or on their surface a pharmaceutical active principle (drug). The invention thus relates to target specific delivery of drugs and/or metal ions. The invention therefore provides compositions containing said aggregates for use as contrast agents, in nuclear medicine or MRI, for the selective delivery of drugs, and for simultaneous delivery of a drug and a metal ion.
    Type: Application
    Filed: May 26, 2006
    Publication date: May 21, 2009
    Inventor: Antonella ACCARDO
  • BIOCONJUGATES OF METAL COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS
    Publication number: 20090098047
    Abstract: The present invention is directed to bioconjugates of complexes represented by the formula: wherein R, R?, R1, R?1, R2, R?2, R3, R?3, R4, R?4, R5, R?5, R6, R?6, R7, R?7, R8, R?8, R9, R?9, M, X, Y, Z and n are defined herein for use as contrast agents in diagnostic imaging.
    Type: Application
    Filed: August 4, 2008
    Publication date: April 16, 2009
    Applicants: Inotek Pharmaceuticals, Kereos, Inc.
    Inventors: William L. Neumann, Dennis P. Riley, Randy H. Weiss, Susan L. Henke, Patrick J. Lennon, Karl W. Aston
  • Octameric Protein For Use In Bionanotechnology Applications
    Publication number: 20090092555
    Abstract: The present invention relates to purified multimeric proteins, comprising PlyCB monomers or functional fragments or variants thereof, which self-assemble into a ring like structure. The present invention also encompasses such multimeric proteins that comprise an integrin-binding sequence. The present invention further discloses contrast reagents, implant coatings, bone implants, and complexes for use in bionanotechnology applications, each of which comprise such multimeric proteins.
    Type: Application
    Filed: July 2, 2008
    Publication date: April 9, 2009
    Inventors: Vincent A. Fischetti, Daniel Craig Nelson, James Charles Whisstock, Ashley Maurice Buckle, Sheena McGowan
  • CONTRAST AGENTS AND METHODS FOR PREPARING CONTRAST AGENTS
    Publication number: 20090087382
    Abstract: Contrast agents comprising a scaffold protein having at least one operative integrated metal ion binding site.
    Type: Application
    Filed: July 13, 2006
    Publication date: April 2, 2009
    Inventors: Jenny J. Yang, Zhi-Ren Liu
  • Enhanced systems and methods for RF-induced hyperthermia
    Patent number: 7510555
    Abstract: A method of inducing hyperthermia in at least a portion of a target area—e.g., a tumor or a portion of a tumor or targeted cancerous cells—is provided. Targeted RF absorption enhancers, e.g., antibodies bound to RF absorbing particles, are introduced into a patient. These targeted RF absorption enhancers will target certain cells in the target areas and enhance the effect of a hyperthermia generating RF signal directed toward the target area. The targeted RF absorption enhancers may, in a manner of speaking, add one or more RF absorption frequencies to cells in the target area, which will permit a hyperthermia generating RF signal at that frequency or frequencies to heat the targeted cells.
    Type: Grant
    Filed: February 3, 2005
    Date of Patent: March 31, 2009
    Assignee: Therm Med, LLC
    Inventor: John Kanzius
  • MRI-Guided Photodynamic Therapy For Cancer
    Publication number: 20090076571
    Abstract: Disclosed is a method of therapy used in combination with a diagnostic tool for enhanced photodynamic therapy using MRI, called (magnetic resonance imaging)-guided photodynamic therapy. The methods of the present invention includes administration of MRI contrast agent labeled polymer photosensitizer conjugates, detection and localization of tumor or cancer tissues with contrast-enhanced MRI and specific illumination and treatment of localized target tissues, such as tumors or cancer cells, using laser energy. The delivered laser energy activates the photosensitizer accumulated in the target tissue, resulting in treatment. Also disclosed are novel conjugate compounds, such as PLGA-Mce6-DOTA-Gd complexes, having multi-functionality in that the complex may include an MRI contrasting agent linked to a photosensitizing agent.
    Type: Application
    Filed: December 2, 2005
    Publication date: March 19, 2009
    Inventors: Zheng-Rong Lu, Anagha Vaidya, Tianyi Ke
  • Peptide for diagnosing, preventing and treating atherosclerosis and uses thereof
    Publication number: 20090074663
    Abstract: A peptide for diagnosing, preventing and treating atherosclerosis, and a use thereof, comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2, and a use thereof. The peptide effectively targets atherosclerotic plaques, and binds to IL-4R to thereby exhibit antagonistic effects on IL-4-mediated signaling of cellular inflammatory reaction and survival reaction. The peptide of the present invention can be used for diagnosis of atherosclerosis, prevention and treatment of IL-4-induced inflammatory reaction and prevention and treatment of atherosclerosis which is primarily caused by the inflammatory reaction, as well as for prevention or treatment of atherosclerosis via conjugation with an anti-atherosclerotic drug.
    Type: Application
    Filed: January 18, 2008
    Publication date: March 19, 2009
    Inventors: Byung Heon Lee, In San Kim, Hai Yan Hong, In Seop So
  • Amine Functionalized Superparamagnetic Nanoparticles for the Synthesis of Bioconjugates and Uses Therefor
    Publication number: 20090068115
    Abstract: Amine functionalized magnetic nanoparticle compositions and processes for synthesizing the same are described. The process consists of obtaining a carboxylated polymer in substantially pure form, which is used to prepare a substantially size homogeneous, polymer coated carboxyl, functionalized magnetic nanoparticle. The carboxyl groups are converted to reactive primary amino groups by the use of a water-soluble carbodiimide followed by reaction of a large excess of a diamine. The amine-terminated nanoparticles are then reacted with bifunctional crosslinking agents and with various biomolecules to make nanoparticles for in vitro assays, cell sorting applications and target specific MR contrast agents.
    Type: Application
    Filed: May 9, 2008
    Publication date: March 12, 2009
    Inventors: Debra A. Gaw, Lee Josephson
  • COMPOSITIONS AND METHODS FOR MAGNETIC RESONANCE IMAGING CONTRAST AGENTS
    Publication number: 20090053141
    Abstract: The present application provides for compositions and methods of creating and applying contrast agents that find use in magnetic resonance imaging (MRI). In particular, contrast agents that comprise monodisperse, protein polymer backbones capable of chelating multiple paramagnetic ions resulting in high relaxivity for use in enhancing MRI signal intensity.
    Type: Application
    Filed: December 7, 2007
    Publication date: February 26, 2009
    Applicant: Northwestern University
    Inventors: Lindsay K. Sulzer, Steven R. Bull, Annelise Emily Barron, Thomas J. Meade
  • PROTEIN CAGES FOR THE DELIVERY OF MEDICAL IMAGING AND THERAPEUTIC AGENTS
    Publication number: 20090041671
    Abstract: The present invention is directed to novel compositions and methods utilizing delivery agents comprising protein cages, medical imaging agents and therapeutic agents.
    Type: Application
    Filed: May 30, 2008
    Publication date: February 12, 2009
    Inventors: Mark J. Young, Trevor Douglas, Yves U. Idzerda
  • Monoclonal Antibodies and Cell Surface Antigens for the Detection and Treatment of Small Cell Lung Cancer (SCLC)
    Publication number: 20090041660
    Abstract: The invention provides new monoclonal antibodies and binding fragments thereof which recognize and immunoreact with cell surface antigens found on small cell lung cancer (SCLC) cells. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of SCLC disease and of patients having SCLC disease. The antibody-recognized SCLC-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing SCLC cells.
    Type: Application
    Filed: September 5, 2008
    Publication date: February 12, 2009
    Inventor: Cohava Gelber
  • BIOMIMETIC IRON-OXIDE-CONTAINING LIPOPROTEIN AND RELATED MATERIALS
    Publication number: 20090035223
    Abstract: An engineered lipoprotein including (a) a core particle or a plurality of core particles, each core particle has (i) an inner part comprising a hydrophilic active agent and a hydrophilic portion of an amphiphilic cholesterol and (ii) an outer part including a hydrophobic portion of the amphiphilic cholesterol, (b) a layer surrounding the core particle or a plurality of core particles, the layer includes a phospholipid, (c) an apoprotein associated with the layer, and optionally, (d) a homing molecule associated with at least one of the apoprotein or the phospholipid.
    Type: Application
    Filed: March 6, 2007
    Publication date: February 5, 2009
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: I-Wei Chen, Hoon Choi